Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2020 Q1- Text added to 2020 Q2
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. senior Avg
|
New words:
AB, Antitrust, Assembly, bear, bill, billed, carryover, constraint, cPR, CT, customary, DDT, degrader, disallow, disallowed, double, entirety, fulfill, GGL, Glaxo, glaxosmithkline, GSK, HSR, impart, infection, inguinal, Ipilimumab, iv, leiomyosarcoma, lesion, liver, lung, lymph, mechanism, modification, modulation, niraparib, Nivo, Nivolumab, node, olaparib, partner, partnered, partnering, PDX, Pembrolizumab, pharmacologically, placement, POLQ, predominant, PRMT, ratio, RECIST, regression, reopening, rescinded, revert, scarce, shelf, Simon, skin, standalone, steering, substance, sum, synergistic, TGI, thereunder, tiered, tomography, trialin, unconditional, uncured, underwritten, unperformed, upfront, vehicle, waiting, weak, wholly
Removed:
Australia, beneficially, Celgene, China, exciting, exert, feel, impactful, leader, leased, LLC, unsolicited
Valuein 2020 Q1 filing- Value in 2020 Q2 filing
Original filings
Filing view